Equity Overview
Price & Market Data
Price: $1.42
Daily Change: $0.00 / 0.00%
Daily Range: $0 - $0
Market Cap: $69,894,168
Daily Volume: 0
Performance Metrics
1 Week: 4.41%
1 Month: 4.41%
3 Months: 2.90%
6 Months: 10.94%
1 Year: 18.33%
YTD: 8.40%
Company Details
Employees: 6
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome. The company is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.